Hiroshi Shiku

List of Publications by Year
in descending order

319 papers	12,024 citations	25034 57 h-index	40979 93 g-index
324 all docs	324 docs citations	324 times ranked	13126 citing authors

#	Article	IF	Citations
1	HDAC Inhibition for Optimized Cellular Immunotherapy of NY-ESO-1-Positive Soft Tissue Sarcoma. Biomedicines, 2022, 10, 373.	3.2	2
2	Distinguishing functional exosomes and other extracellular vesicles as a nucleic acid cargo by the anionâ€exchange method. Journal of Extracellular Vesicles, 2022, 11, e12205.	12.2	29
3	Prognostic significance of NY-ESO-1 antigen and PIGR expression in esophageal tumors of CHP-NY-ESO-1-vaccinated patients as adjuvant therapy. Cancer Immunology, Immunotherapy, 2022, 71, 2743-2755.	4.2	2
4	Self-assembled polysaccharide nanogel delivery system for overcoming tumor immune resistance. Journal of Controlled Release, 2022, 347, 175-182.	9.9	22
5	NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome. , 2022, 10, e003811.		26
6	Safety and antibody immune response of CHP-NY-ESO-1 vaccine combined with poly-ICLC in advanced or recurrent esophageal cancer patients. Cancer Immunology, Immunotherapy, 2021, 70, 3081-3091.	4.2	20
7	Evaluation of Production Protocols for the Generation of NY-ESO-1-Specific T Cells. Cells, 2021, 10, 152.	4.1	2
8	Development of INSOLâ€tag for proteomeâ€wide protein handling and its application in protein array analysis. Genes To Cells, 2020, 25, 41-53.	1.2	0
9	MAGE-A4, NY-ESO-1 and SAGE mRNA expression rates and co-expression relationships in solid tumours. BMC Cancer, 2020, 20, 606.	2.6	25
10	First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors. Cancer Immunology, Immunotherapy, 2020, 69, 663-675.	4.2	22
11	Development of a Unique T Cell Receptor Gene-Transferred Tax-Redirected T Cell Immunotherapy for Adult T Cell Leukemia. Biology of Blood and Marrow Transplantation, 2020, 26, 1377-1385.	2.0	14
12	Relationship between T cell receptor clonotype and PDâ€1 expression of tumorâ€infiltrating lymphocytes in colorectal cancer. European Journal of Immunology, 2020, 50, 1580-1590.	2.9	3
13	CD4 + T cells support polyfunctionality of cytotoxic CD8 + T cells with memory potential in immunological control of tumor. Cancer Science, 2020, 111, 1958-1968.	3.9	19
14	Nanogel antigen DDS toward overcoming immune resistance of cancer. Drug Delivery System, 2020, 35, 64-69.	0.0	0
15	Comparison of IL-2 vs IL-7/IL-15 for the generation of NY-ESO-1-specific T cells. Cancer Immunology, Immunotherapy, 2019, 68, 1195-1209.	4.2	27
16	Immunohistochemical expression and clinicopathological assessment of the cancer testis antigens NYâ€ESOâ€1 and MAGEâ€A4 in highâ€grade softâ€tissue sarcoma. Oncology Letters, 2019, 17, 3937-3943.	1.8	29
17	First Case of Cytokine Release Syndrome after Nivolumab for Gastric Cancer. Case Reports in Oncology, 2019, 12, 147-156.	0.7	28
18	Exosomal regulation of lymphocyte homing to the gut. Blood Advances, 2019, 3, 1-11.	5.2	52

#	Article	IF	Citations
19	Antigen delivery targeted to tumor-associated macrophages overcomes tumor immune resistance. Journal of Clinical Investigation, 2019, 129, 1278-1294.	8.2	102
20	Tumor responses and early onset cytokine release syndrome in synovial sarcoma patients treated with a novel affinity-enhanced NY-ESO-1-targeting TCR-redirected T cell transfer.. Journal of Clinical Oncology, 2019, 37, 2530-2530.	1.6	6
21	Phase I/II clinical trial of NY-ESO-1-specific TCR-engineered T-cell transfer combined with a novel T-cell stimulator CHP:NE1 for patients with refractory soft tissue sarcoma.. Journal of Clinical Oncology, 2019, 37, TPS11074-TPS11074.	1.6	1
22	Activated CD8+ T cell extracellular vesicles prevent tumour progression by targeting of lesional mesenchymal cells. Nature Communications, 2018, 9, 435.	12.8	139
23	Serum immunoglobulin E response as a marker for unfavorable prognosis following cholesteryl pullulan-MAGE A4 vaccination. Oncology Letters, 2018, 15, 3703-3711.	1.8	1
24	Prognostic value of MAGEA4 in primary lung cancer depends on subcellular localization and p53 status. International Journal of Oncology, 2018, 53, 713-724.	3.3	7
25	Antitumor activity of CAR-T cells targeting the intracellular oncoprotein WT1 can be enhanced by vaccination. Blood, 2018, 132, 1134-1145.	1.4	73
26	Exosomeâ€mediated regulation of tumor immunology. Cancer Science, 2018, 109, 2998-3004.	3.9	119
27	First-in-human phase I clinical trial of NY-ESO-1 protein cancer vaccine with a novel adjuvant MIS416, NOD2 and TLR9 stimulant, for patients with NY-ESO-1 expressing solid tumors.. Journal of Clinical Oncology, 2018, 36, e15176-e15176.	1.6	1
28	Pertuzumab, trastuzumab and eribulin mesylate therapy for previously treated advanced HER2-positive breast cancer: a feasibility study with analysis of biomarkers. Oncotarget, 2018, 9, 14909-14921.	1.8	6
29	NY-ESO-1 antigen expression and immune response are associated with poor prognosis in MAGE-A4-vaccinated patients with esophageal or head/neck squamous cell carcinoma. Oncotarget, 2018, 9, 35997-36011.	1.8	12
30	Clinical Implications of CD4+CD25+Foxp3+Regulatory T Cell Frequencies After CHP-MAGE-A4 Cancer Vaccination. Anticancer Research, 2018, 38, 1435-1444.	1.1	2
31	Identification of an immunogenic neo-epitope encoded by mouse sarcoma using CXCR3 ligand mRNAs as sensors. OncoImmunology, 2017, 6, e1306617.	4.6	5
32	Safety and persistence of WT1-specific T-cell receptor geneâ^'transduced lymphocytes in patients with AML and MDS. Blood, 2017, 130, 1985-1994.	1.4	127
33	Attempt to Harvest a Sufficient Number of Mononuclear Cells in an Appropriate Blood Product Volume By Modification of the Default Apheresis Setting. Therapeutic Apheresis and Dialysis, 2017, 21, 507-511.	0.9	0
34	[OPINION] Problems of cancer vaccine therapy development. Drug Delivery System, 2017, 32, 172-173.	0.0	0
35	Signal-transducing adaptor protein-2 promotes generation of functional long-term memory CD8+ T cells by preventing terminal effector differentiation. Oncotarget, 2017, 8, 30766-30780.	1.8	9
36	Abstract PR02: Antigen delivery targeting tumor-infiltrating macrophages leads to eradication of tumor highly resistant to immune checkpoint inhibitors. , 2017, , .		0

#	Article	IF	Citations
37	Epirubicin, Identified Using a Novel Luciferase Reporter Assay for Foxp3 Inhibitors, Inhibits Regulatory T Cell Activity. PLoS ONE, 2016, 11, e0156643.	2.5	14
38	193. Efficacy and Safety of Immunotherapy with Chimeric Antigen Receptor Targeting WT1 and HLA-A24:02 pMHC Complex. Molecular Therapy, 2016, 24, S75-S76.	8.2	1
39	PD32-05 PHASE I CLINICAL STUDY ON THE COMBINATION THERAPY OF CHP-NY-ESO-1 CANCER VACCINE AND MIS416 FOR THE TREATMENT OF PATIENTS WITH NY-ESO-1 EXPRESSING REFRACTORY UROTHELIAL CANCER OR CASTRATION-RESISTANT PROSTATE CANCER. Journal of Urology, 2016, 195, .	0.4	1
40	Development of Engineered T Cells Expressing a Chimeric CD16-CD3Î¶ Receptor to Improve the Clinical Efficacy of Mogamulizumab Therapy Against Adult T-Cell Leukemia. Clinical Cancer Research, 2016, 22, 4405-4416.	7.0	20
41	Engineering hybrid exosomes by membrane fusion with liposomes. Scientific Reports, 2016, 6, 21933.	3.3	447
42	Efficient tumor regression by adoptively transferred CEA-specific CAR-T cells associated with symptoms of mild cytokine release syndrome. OncoImmunology, 2016, 5, e1211218.	4.6	36
43	Time-dependent transition of the immunoglobulin G subclass and immunoglobulin E response in cancer patients vaccinated with cholesteryl pullulan-melanoma antigen gene-A4 nanogel. Oncology Letters, 2016, 12, 4493-4504.	1.8	26
44	CD8 ⁺ CD122 ⁺ CD49d ^{low} regulatory T cells maintain T-cell homeostasis by killing activated T cells via Fas/FasL-mediated cytotoxicity. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 2460-2465.	7.1	55
45	Clinical relevance of antigen spreading pattern induced by CHP-MAGE-A4 cancer vaccination. Immunotherapy, 2016, 8, 527-540.	2.0	10
46	Phase 1 Clinical Trial of Adoptive Immunotherapy for Acute Myelogenous Leukemia and Myelodysplastic Syndrome, Using Gene-Modified Autologous Lymphocytes Expressing WT1-Specific T-Cell Receptor. Blood, 2016, 128, 1653-1653.	1.4	2
47	Guanine-Rich Sequences Are a Dominant Feature of Exosomal microRNAs across the Mammalian Species and Cell Types. PLoS ONE, 2016, 11, e0154134.	2.5	15
48	A Functionally Superior Second-Generation Vector Expressing an Aurora Kinase-A-Specific T-Cell Receptor for Anti-Leukaemia Adoptive Immunotherapy. PLoS ONE, 2016, 11, e0156896.	2.5	0
49	Tumor-Specific Donor Lymphocyte Infusion for Tumor Relapse after MHC-Haploidentical Hematopoietic Stem Cell Transplantation. Blood, 2016, 128, 2157-2157.	1.4	0
50	2015 Guidance on cancer immunotherapy development in earlyâ€phase clinical studies. Cancer Science, 2015, 106, 1761-1771.	3.9	16
51	Direct tumor recognition by a human CD4+ T-cell subset potently mediates tumor growth inhibition and orchestrates anti-tumor immune responses. Scientific Reports, 2015, 5, 14896.	3.3	70
52	Adoptive immunotherapy of cancer utilizing genetically engineered lymphocytes. Cancer Immunology, Immunotherapy, 2015, 64, 903-909.	4.2	3
53	Antileukemia multifunctionality of CD4+ T cells genetically engineered by HLA class I-restricted and WT1-specific T-cell receptor gene transfer. Leukemia, 2015, 29, 2393-2401.	7.2	12
54	Gene expression profiling of diffuse large B-Cell lymphomas supervised by CD5 expression. International Journal of Hematology, 2015, 102, 188-194.	1.6	25

#	Article	IF	Citations
55	Adoptive Transfer of MAGE-A4 T-cell Receptor Gene-Transduced Lymphocytes in Patients with Recurrent Esophageal Cancer. Clinical Cancer Research, 2015, 21, 2268-2277.	7.0	139
56	Immunotherapy with Chimeric Antigen Receptor Targeting Intracellular WT1 Gene Product Complexed with HLA-a*24:02 Molecule. Blood, 2015, 126, 4292-4292.	1.4	5
57	Adoptive Transfer of WT1-Specific TCR Gene-Transduced Lymphocytes in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia. Blood, 2015, 126, 97-97.	1.4	3
58	Abstract B34: Signal transducing adaptor protein 2 (STAP2) has the crucial role in maintaining the CTL function of memory T cells. , 2015, , .		0
59	Targeting Aurora Kinase with a Superior T-Cell Receptor Gene-Transfer Vector. Blood, 2015, 126, 4291-4291.	1.4	0
60	Systemic CD8+ T Cell-Mediated Tumoricidal Effects by Intratumoral Treatment of Oncolytic Herpes Simplex Virus with the Agonistic Monoclonal Antibody for Murine Glucocorticoid-Induced Tumor Necrosis Factor Receptor. PLoS ONE, 2014, 9, e104669.	2.5	12
61	Classification of current anticancer immunotherapies. Oncotarget, 2014, 5, 12472-12508.	1.8	395
62	Stimulation through very late antigenâ€4 and â€5 improves the multifunctionality and memory formation of CD8⁺ TÂcells. European Journal of Immunology, 2014, 44, 1747-1758.	2.9	9
63	Adoptive transfer of genetically engineered WT1-specific cytotoxic T lymphocytes does not induce renal injury. Journal of Hematology and Oncology, 2014, 7, 3.	17.0	4
64	Gene-Modified Human Î±/Î²-T Cells Expressing a Chimeric CD16-CD3Î¶ Receptor as Adoptively Transferable Effector Cells for Anticancer Monoclonal Antibody Therapy. Cancer Immunology Research, 2014, 2, 249-262.	3.4	38
65	Nanogel-Based Immunologically Stealth Vaccine Targets Macrophages in the Medulla of Lymph Node and Induces Potent Antitumor Immunity. ACS Nano, 2014, 8, 9209-9218.	14.6	117
66	High expression of MAGE-A4 and MHC class I antigens in tumor cells and induction of MAGE-A4 immune responses are prognostic markers of CHP-MAGE-A4 cancer vaccine. Vaccine, 2014, 32, 5901-5907.	3.8	54
67	Interleukin-17 Induces an Atypical M2-Like Macrophage Subpopulation That Regulates Intestinal Inflammation. PLoS ONE, 2014, 9, e108494.	2.5	53
68	Tumor- and Immune Cell-Derived Exosomes. Drug Delivery System, 2014, 29, 152-159.	0.0	1
69	Abstract CT212: Adoptive transfer of wild-type TCR gene transduced T lymphocytes targeting MAGE-A4 antigen to patients with refractory esophageal cancer. , 2014, , .		0
70	Tumor-Specific TCR-Engineered Donor Lymphocyte Infusion Therapy with Reduced GvHD Induction Utilizing Novel Retrovirus Vector Silencing Endogenous TCR Expression. Blood, 2014, 124, 656-656.	1.4	0
71	Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients. Journal of Translational Medicine, 2013, 11, 246.	4.4	94
72	Establishment of animal models to analyze the kinetics and distribution of human tumor antigen-specific CD8+ T cells. Vaccine, 2013, 31, 2110-2118.	3.8	6

#	Article	IF	Citations
73	Manipulation of human early T lymphopoiesis by coculture on human bone marrow stromal cells: Potential utility for adoptive immunotherapy. Experimental Hematology, 2013, 41, 367-376.e1.	0.4	1
74	Adoptive transfer of genetically modified Wilms' tumor 1â€“specific T cells in a novel malignant skull base meningioma model. Neuro-Oncology, 2013, 15, 747-758.	1.2	12
75	Overcoming regulatory Tâ€cell suppression by a lyophilized preparation of Streptococcus pyogenes. European Journal of Immunology, 2013, 43, 989-1000.	2.9	8
76	Development of a novel redirected T-cellâ€“based adoptive immunotherapy targeting human telomerase reverse transcriptase for adult T-cell leukemia. Blood, 2013, 121, 4894-4901.	1.4	40
77	Limited expression of cancer-testis antigens in renal cell carcinoma patients. Molecular and Clinical Oncology, 2013, 1, 326-330.	1.0	9
78	Co-Introduced Functional CCR2 Potentiates In Vivo Anti-Lung Cancer Functionality Mediated by T Cells Double Gene-Modified to Express WT1-Specific T-Cell Receptor. PLoS ONE, 2013, 8, e56820.	2.5	39
79	Abstract B11: Control of in vivo spatiotemporal dynamics of antigen and adjuvant by a delivery system CHP nanogel markedly improves the immunogenicity and antitumor efficacy of long peptide cancer vaccine.. , 2013, , .		0
80	A novel human-derived antibody against NY-ESO-1 improves the efficacy of chemotherapy. Cancer Immunity, 2013, 13, 3.	3.2	10
81	A Promising Vector for TCR Gene Therapy: Differential Effect of siRNA, 2A Peptide, and Disulfide Bond on the Introduced TCR Expression. Molecular Therapy - Nucleic Acids, 2012, 1, e63.	5.1	34
82	Aurora kinase A-specific T-cell receptor gene transfer redirects T lymphocytes to display effective antileukemia reactivity. Blood, 2012, 119, 368-376.	1.4	24
83	Peptide-pulsed dendritic cell vaccination targeting interleukin-13 receptor Î±2 chain in recurrent malignant glioma patients with HLA-A*24/A*02 allele. Cytotherapy, 2012, 14, 733-742.	0.7	56
84	Cancer immunotherapy; integration of T cell biology with nanogel- and vector-technology in translational research. Arthritis Research and Therapy, 2012, 14, .	3.5	0
85	siRNA-mediated silencing of PD-1 ligands enhances tumor-specific human T-cell effector functions. Gene Therapy, 2012, 19, 959-966.	4.5	57
86	Intracellular Tumor-Associated Antigens Represent Effective Targets for Passive Immunotherapy. Cancer Research, 2012, 72, 1672-1682.	0.9	46
87	Antigen-Receptor Gene-Modified T Cells For Treatment Of Glioma. Advances in Experimental Medicine and Biology, 2012, 746, 202-215.	1.6	7
88	Tâ€cell receptor gene therapy targeting melanomaâ€associated antigenâ€A4 inhibits human tumor growth in nonâ€obese diabetic/SCID/Iˡ³c^{null} mice. Cancer Science, 2012, 103, 17-25.	3.9	26
89	Human bone marrow stromal cells simultaneously support <scp>B</scp> and <scp>T</scp>/<scp>NK</scp> lineage development from human haematopoietic progenitors: a principal role for flt3 ligand in lymphopoiesis. British Journal of Haematology, 2012, 157, 674-686.	2.5	12
90	The possibility of antigenic peptide, protein and DNA delivery by percutaneous vaccination. Drug Delivery System, 2012, 27, 194-201.	0.0	0

#	Article	IF	Citations
91	Therapeutically Infused Redirected T Cells Targeting WT1 Successfully Inhibited Leukemia Stem Cells in Vivo. Blood, 2012, 120, 4221-4221.	1.4	0
92	Defining the critical hurdles in cancer immunotherapy. Journal of Translational Medicine, 2011, 9, 214.	4.4	139
93	Myelodysplastic Syndrome of del 20q with Plasma Cell Dysplasia. Journal of Clinical and Experimental Hematopathology: JCEH, 2011, 51, 141-145.	0.8	2
94	Intratumoral Injection of Propionibacterium acnes Suppresses Malignant Melanoma by Enhancing Th1 Immune Responses. PLoS ONE, 2011, 6, e29020.	2.5	28
95	Novel adoptive T-cell immunotherapy using a WT1-specific TCR vector encoding silencers for endogenous TCRs shows marked antileukemia reactivity and safety. Blood, 2011, 118, 1495-1503.	1.4	114
96	Gemcitabine enhances Wilmsâ€™ tumor gene WT1 expression and sensitizes human pancreatic cancer cells with WT1-specific T-cell-mediated antitumor immune response. Cancer Immunology, Immunotherapy, 2011, 60, 1289-1297.	4.2	46
97	UV irradiation of immunized mice induces type 1 regulatory T cells that suppress tumor antigen specific cytotoxic T lymphocyte responses. International Journal of Cancer, 2011, 129, 1126-1136.	5.1	19
98	Feasibility of gene-immunotherapy using WT1-specific T-cell receptor gene transfer for infant acute lymphoblastic leukemia with MLL gene rearrangement. Blood Cancer Journal, 2011, 1, e10-e10.	6.2	0
99	A clinical trial of combined immunotherapy with MAGE-A4 peptide and cultured T lymphocyte for patients with head and neck squamous cell carcinoma. Japanese Journal of Head and Neck Cancer, 2011, 37, 366-369.	0.1	0
100	Forced Expression of CC Chemokine Receptor 2 Enhances Anti-Cancer Reactivity Mediated by T Lymphocytes Beforehand Redirected Toward WT1 Inside the Tumor Microenvironment. Blood, 2011, 118, 2059-2059.	1.4	0
101	Tumor-specific Crosslinking of GITR as Costimulation for Immunotherapy. Journal of Immunotherapy, 2010, 33, 925-934.	2.4	15
102	Thioredoxin suppresses airway inflammation independently of systemic Th1/Th2 immune modulation. European Journal of Immunology, 2010, 40, 787-796.	2.9	37
103	NYâ€ESOâ€1 protein glycosylated by yeast induces enhanced immune responses. Yeast, 2010, 27, 919-931.	1.7	5
104	Two Distinct Mechanisms of Augmented Antitumor Activity by Modulation of Immunostimulatory/Inhibitory Signals. Clinical Cancer Research, 2010, 16, 2781-2791.	7.0	118
105	Peptide Vaccine Induces Enhanced Tumor Growth Associated with Apoptosis Induction in CD8+ T Cells. Journal of Immunology, 2010, 185, 3768-3776.	0.8	47
106	UV irradiation after immunization induces type 1 regulatory T cells that suppress Th2-type immune responses via secretion of IL-10. Immunobiology, 2010, 215, 124-132.	1.9	16
107	Polyvalent Cancer Vaccine with a Novel Antigen Delivery System, CHP (cholesterol bearing) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T	0.0	0
108	Abstract 5615: Effects of corticosteroids on tumor immunity induced by anti-CTLA-4 mAb therapy in a mouse model. , 2010, , .		0

#	Article	IF	Citations
109	Abstract 4751: Peptide vaccine induces apoptosis of antigen-specific CD8+T cells. , 2010, , .		0
110	Augmented Expression of WT1-Specific TCR and Inhibition of Mispaired-TCR Formation In TCR-Gene Modified T-Cells Can Concomitantly Be Achieved Using a Novel Retroviral Vector with Silencers for Endogenous TCRs. Blood, 2010, 116, 1020-1020.	1.4	0
111	Engineering of Human T-Cells with a Novel Aurora-A Kinase-Specific T-Cell Receptor Gene Transfer Confers Anti-Leukemia Reactivity. Blood, 2010, 116, 4290-4290.	1.4	0
112	IFN-Î³-dependent type 1 immunity is crucial for immunosurveillance against squamous cell carcinoma in a novel mouse carcinogenesis model. Carcinogenesis, 2009, 30, 1408-1415.	2.8	33
113	Tumor progression inhibits the induction of multifunctionality in adoptively transferred tumorâ€specific CD8⁺ T cells. European Journal of Immunology, 2009, 39, 241-253.	2.9	50
114	Glucocorticoidâ€induced tumor necrosis factor receptor stimulation enhances the multifunctionality of adoptively transferred tumor antigenâ€specific CD8⁺ T cells with tumor regression. Cancer Science, 2009, 100, 1317-1325.	3.9	34
115	Rapid Î±Î² TCR-mediated responses in Î³Î´ T cells transduced with cancer-specific TCR genes. Gene Therapy, 2009, 16, 620-628.	4.5	59
116	Antibody responses against NY-ESO-1 and HER2 antigens in patients vaccinated with combinations of cholesteryl pullulan (CHP)-NY-ESO-1 and CHP-HER2 with OK-432. Vaccine, 2009, 27, 6854-6861.	3.8	45
117	Improved Expression and Reactivity of Transduced Tumor-Specific TCRs in Human Lymphocytes by Specific Silencing of Endogenous TCR. Cancer Research, 2009, 69, 9003-9011.	0.9	174
118	Gene expression profiling of peripheral T-cell lymphoma including Î³Î´ T-cell lymphoma. Blood, 2009, 113, 1071-1074.	1.4	64
119	Development of Novel Stem Cell Transplantation and Gene-Immunotherapy Using WT1-Specific T-Cell Receptor Gene.. Blood, 2009, 114, 3028-3028.	1.4	0
120	Biliary Carcinomas Induced in the Hamster. , 2009, , 69-94.		0
121	Induction of immune response against NY-ESO-1 by CHP-NY-ESO-1 vaccination and immune regulation in a melanoma patient. Cancer Immunology, Immunotherapy, 2008, 57, 1429-1437.	4.2	40
122	Analysis of peripheral and local antiâ€tumor immune response in esophageal cancer patients after NYâ€ESOâ€1 protein vaccination. International Journal of Cancer, 2008, 123, 2362-2369.	5.1	46
123	Long-term phenotypic, functional and genetic stability of cancer-specific T-cell receptor (TCR) Î±Î² genes transduced to CD8+ T cells. Gene Therapy, 2008, 15, 695-699.	4.5	19
124	Humoral immune responses in patients vaccinated with 1â€“146 HER2 protein complexed with cholesteryl pullulan nanogel. Cancer Science, 2008, 99, 601-607.	3.9	117
125	Gene expression profiling of diffuse large Bâ€cell lymphoma supervised by CD21 expression. British Journal of Haematology, 2008, 142, 562-570.	2.5	12
126	Importance of CD80/CD86â€“CD28 interactions in the recognition of target cells by CD8+CD122+regulatory T cells. Immunology, 2008, 124, 121-128.	4.4	43

#	Article	IF	Citations
127	Differential Regulatory Function of Resting and Preactivated Allergen-Specific CD4+CD25+ Regulatory T Cells in Th2-Type Airway Inflammation. Journal of Immunology, 2008, 181, 6889-6897.	0.8	40
128	Post-immune UV irradiation induces Tr1-like regulatory T cells that suppress humoral immune responses. International Immunology, 2008, 20, 57-70.	4.0	25
129	CD8+CD122+ regulatory T cells recognize activated T cells via conventional MHC class Iâ€“Î±Î²TCR interaction and become IL-10-producing active regulatory cells. International Immunology, 2008, 20, 937-947.	4.0	95
130	Regulatory T Cellâ€“Resistant CD8+ T Cells Induced by Glucocorticoid-Induced Tumor Necrosis Factor Receptor Signaling. Cancer Research, 2008, 68, 5948-5954.	0.9	80
131	The Membrane Proteinase 3 Expression on Neutrophils Was Downregulated After Treatment With Infliximab in Patients With Rheumatoid Arthritis. Clinical and Applied Thrombosis/Hemostasis, 2008, 14, 186-192.	1.7	20
132	De novo CD5+ diffuse large B-cell lymphoma: results of a detailed clinicopathological review in 120 patients. Haematologica, 2008, 93, 1195-1202.	3.5	113
133	RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses. Blood, 2008, 111, 1357-1365.	1.4	202
134	Hematopoietic origin of hepatic stellate cells in the adult liver. Blood, 2008, 111, 2427-2435.	1.4	79
135	Induction of regulatory T cellâ€“resistant helper CD4+ T cells by bacterial vector. Blood, 2008, 111, 1404-1412.	1.4	28
136	Preclinical safety pharmacology study of a novel protein-based cancer vaccine CHP-NY-ESO-1. Kobe Journal of Medical Sciences, 2008, 54, E23-34.	0.2	6
137	Early Tumor Regression Following Severe Lung Injury after Allogeneic Stem Cell Transplantation in a Patient with Renal Cell Carcinoma. Internal Medicine, 2007, 46, 291-293.	0.7	0
138	Decreased ADAMTS13 activity in plasma from patients with thrombotic thrombocytopenic purpura. Thrombosis Research, 2007, 119, 447-452.	1.7	19
139	Reduced Cd4+Cd25+ T cells in patients with idiopathic thrombocytopenic purpura. Thrombosis Research, 2007, 120, 187-193.	1.7	143
140	Antibody response against NY-ESO-1 in CHP-NY-ESO-1 vaccinated patients. International Journal of Cancer, 2007, 120, 2178-2184.	5.1	68
141	Detection of the CBFB/MYH11 fusion gene in de novo acute myeloid leukemia (AML): A single-institution study of 224 Japanese AML patients. Leukemia Research, 2007, 31, 471-476.	0.8	17
142	Notch ligand Delta-1 differentially modulates the effects of gp130 activation on interleukin-6 receptor ?-positive and -negative human hematopoietic progenitors. Cancer Science, 2007, 98, 1597-1603.	3.9	13
143	Clinicopathologic Significance of Loss of CD19 Expression in Diffuse Large B-Cell Lymphoma. International Journal of Hematology, 2007, 85, 41-48.	1.6	9
144	Immunological and Clinical Responses in Patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Multiple Myeloma (MM) and Chronic Lymphocytic Leukemia (CLL) after RHAMM-R3 Peptide Vaccination.. Blood, 2007, 110, 1806-1806.	1.4	9

#	Article	IF	Citations
145	T cell immunomonitoring and tumor responses in patients immunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein. Cancer Immunity, 2007, 7, 9.	3.2	87
146	Hemostatic abnormalities and leukocyte activation caused by infection in patients with malignant lymphoma during chemotherapy. Thrombosis Research, 2006, 117, 671-679.	1.7	10
147	De novo CD5-positive Diffuse Large B-cell Lymphoma of the Temporal Bone Presenting with an External Auditory Canal Tumor. Internal Medicine, 2006, 45, 733-737.	0.7	19
148	PROTEINASE 3 EXPRESSION ON NEUTROPHIL MEMBRANES FROM PATIENTS WITH INFECTIOUS DISEASE. Shock, 2006, 26, 128-133.	2.1	18
149	Pleiotropic role of histone deacetylases in the regulation of human adult erythropoiesis. British Journal of Haematology, 2006, 135, 242-253.	2.5	26
150	Differential cell division history between neutrophils and macrophages in their development from granulocyte?macrophage progenitors. British Journal of Haematology, 2006, 135, 725-731.	2.5	11
151	Expression profiling analysis of the CD5+ diffuse large B-cell lymphoma subgroup: Development of a CD5 signature. Cancer Science, 2006, 97, 868-874.	3.9	56
152	Haunting appearance of bcr/abl fusion gene products in a patient with therapy related leukaemia. Leukemia Research, 2006, 30, 106-108.	0.8	4
153	Low p53 expression of acute myelocytic leukemia cells with t(8;21) chromosome abnormality: Association with low p14ARF expression. Leukemia Research, 2006, 30, 379-383.	0.8	10
154	Granulocytic sarcoma of mesentery in acute myeloid leukemia with CBFB/MYH11 fusion gene but not inv(16) chromosome: Case report and review of literature. Leukemia Research, 2006, 30, 1053-1057.	0.8	22
155	Mutational analysis of the KIT gene in myelodysplastic syndrome (MDS) and MDS-derived leukemia. Leukemia Research, 2006, 30, 1235-1239.	0.8	28
156	Development of Mixed-Type Autoimmune Hemolytic Anemia and Evans' Syndrome following Chicken Pox Infection in a Case of Low-Titer Cold Agglutinin Disease. International Journal of Hematology, 2006, 84, 220-223.	1.6	11
157	Bilateral Osteonecrosis of the Head of the Femur during Treatment with Retinoic Acid in a Young Patient with Acute Promyelocytic Leukemia. International Journal of Hematology, 2006, 83, 252-253.	1.6	8
158	Features of early gastric cancer and gastric adenoma by enhanced-magnification endoscopy. Journal of Gastroenterology, 2006, 41, 332-338.	5.1	54
159	Molecular analysis of PDGFRalpha/beta genes in core binding factor leukemia with eosinophilia. European Journal of Haematology, 2006, 76, 18-22.	2.2	10
160	Molecular and phenotypic analysis of Philadelphia chromosome-positive bilineage leukemia: possibility of a lineage switch from T-lymphoid leukemic progenitor to myeloid cells. Cancer Genetics and Cytogenetics, 2006, 164, 118-121.	1.0	23
161	Contrast-enhanced ultrasound examination of lymph nodes in different types of lymphoma. Cancer Detection and Prevention, 2006, 30, 188-191.	2.1	29
162	Generation of peptide-specific CD8+ T cells by phytohemagglutinin-stimulated antigen-mRNA-transduced CD4+ T cells. Journal of Immunological Methods, 2006, 314, 54-66.	1.4	16

#	Article	IF	Citations
163	Frequency of Abnormal Biphasic aPTT Clot Waveforms in Patients with Underlying Disorders Associated with Disseminated Intravascular Coagulation. Clinical and Applied Thrombosis/Hemostasis, 2006, 12, 185-192.	1.7	48
164	In vitro Stimulation of CD8 and CD4 T Cells by Dendritic Cells Loaded with a Complex of Cholesterol-Bearing Hydrophobized Pullulan and NY-ESO-1 Protein: Identification of a New HLA-DR15â€“Binding CD4 T-Cell Epitope. Clinical Cancer Research, 2006, 12, 1921-1927.	7.0	44
165	HER2-Specific T-Cell Immune Responses in Patients Vaccinated with Truncated HER2 Protein Complexed with Nanogels of Cholesteryl Pullulan. Clinical Cancer Research, 2006, 12, 7397-7405.	7.0	115
166	In vivo antigen delivery by aSalmonella typhimurium type III secretion system for therapeutic cancer vaccines. Journal of Clinical Investigation, 2006, 116, 1946-1954.	8.2	164
167	Gene Expression Profiling of Diffuse Large B-Cell Lymphomas Supervised by CD21 Expression.. Blood, 2006, 108, 2029-2029.	1.4	3
168	Thrombomodulin accelerates activated protein C production and inhibits thrombin generation in the plasma of disseminated intravascular coagulation patients. Blood Coagulation and Fibrinolysis, 2005, 16, 17-24.	1.0	7
169	Acute interstitial pneumonitis during chemotherapy for haematological malignancy. European Journal of Cancer Care, 2005, 14, 336-341.	1.5	9
170	Elevated levels of soluble interleukin-2 receptor in serum of patients with hematological or non-hematological malignancies. Cancer Detection and Prevention, 2005, 29, 256-259.	2.1	26
171	Inhibition by Rho-kinase and protein kinase C of myosin phosphatase is involved in thrombin-induced shape change of megakaryocytic leukemia cell line UT-7/TPO. Cellular Signalling, 2005, 17, 321-330.	3.6	9
172	Effects of atorvastatin on serum lipids, lipoproteins, and hemostasis. American Journal of Hematology, 2005, 78, 1-6.	4.1	9
173	Haemostatic abnormalities and thrombotic disorders in malignant lymphoma. Thrombosis and Haemostasis, 2005, 93, 153-159.	3.4	34
174	Elevated Plasma Levels of Fibrin Degradation Productsby Granulocyte-Derived Elastase in Patients with Disseminated Intravascular Coagulation. Clinical and Applied Thrombosis/Hemostasis, 2005, 11, 391-400.	1.7	22
175	Accelerated chemically induced tumor development mediated by CD4+CD25+ regulatory T cells in wild-type hosts. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 9253-9257.	7.1	102
176	IFN-Î³ Controls the Generation/Activation of CD4+CD25+ Regulatory T Cells in Antitumor Immune Response. Journal of Immunology, 2005, 175, 4433-4440.	0.8	92
177	Definition of target antigens for naturally occurring CD4+ CD25+ regulatory T cells. Journal of Experimental Medicine, 2005, 201, 681-686.	8.5	118
178	Usefulness of Measurement of Reticulated Platelets for Diagnosis of Idiopathic Thrombocytopenic Purpura. Clinical and Applied Thrombosis/Hemostasis, 2005, 11, 253-261.	1.7	16
179	Determination of Cellularly Processed HLA-A2402-Restricted Novel CTL Epitopes Derived from Two Cancer Germ Line Genes, MAGE-A4 and SAGE. Clinical Cancer Research, 2005, 11, 5581-5589.	7.0	51
180	A novel role for Notch ligand Delta-1 as a regulator of human Langerhans cell development from blood monocytes. Journal of Leukocyte Biology, 2005, 78, 921-929.	3.3	57

#	Article	IF	Citations
181	Usefulness of Fully Automated Measurement of Reticulated Platelets Using Whole Blood. Clinical and Applied Thrombosis/Hemostasis, 2005, 11, 263-270.	1.7	15
182	IL-4 and IL-10 synergistically inhibit survival of human blood monocytes supported by GM-CSF. International Journal of Oncology, 2005, 26, 731.	3.3	6
183	Expression of CD29 on lymphoma cells and/or CD36 on microvascular endothels correlates with high serum LDH level in diffuse large B-cell lymphomas (DLBCLs) and is frequent in de novo CD5-positive DLBCLs. International Journal of Oncology, 2005, 27, 1241.	3.3	4
184	Prognostic Impact of Aortic Calcification Index and Ankle-Arm Blood Pressure Indexin Patients under Hemodialysis. Clinical and Applied Thrombosis/Hemostasis, 2005, 11, 161-169.	1.7	4
185	Rho-kinase induces association of adducin with the cytoskeleton in platelet activation. Biochemical and Biophysical Research Communications, 2005, 332, 347-351.	2.1	13
186	Elevated plasma levels of fibrin degradation products by granulocyte-derived elastase in patients with deep vein thrombosis. Thrombosis Research, 2005, 115, 53-57.	1.7	16
187	Elevated levels of leukocyte tissue factor mRNA in patients with venous thromboembolism. Thrombosis Research, 2005, 116, 307-312.	1.7	26
188	CD19-Negative Diffuse Large B-Cell Lymphoma Shows High Serum LDH Level and Poor Prognosis.. Blood, 2005, 106, 1924-1924.	1.4	24
189	Distinct Characteristics of t(8;21) Acute Myeloid Leukemia with Active KIT Mutation.. Blood, 2005, 106, 3297-3297.	1.4	1
190	Tissue factor messenger RNA levels in leukocytes compared with tissue factor antigens in plasma from patients in hypercoagulable state caused by various diseases. Thrombosis and Haemostasis, 2004, 92, 132-139.	3.4	22
191	Hemostatic Abnormalities and Changes Following Bone Marrow Transplantation. Clinical and Applied Thrombosis/Hemostasis, 2004, 10, 341-350.	1.7	18
192	Pathway analysis of informative genes from microarray data reveals that metabolism and signal transduction genes distinguish different subtypes of lymphomas. International Journal of Oncology, 2004, 24, 497.	3.3	4
193	Acute myeloid leukemia with t(8;21)(q22;q22) manifesting as granulocytic sarcomas in the rhinopharynx and external acoustic meatus at relapse after high-dose cytarabine: case report and review of the literature. The Hematology Journal, 2004, 5, 84-89.	1.4	30
194	Upregulated production of IL-6, but not IL-10, by interferon-Î± induces SOCS3 expression and attenuates STAT1 phosphorylation in myeloma cells. The Hematology Journal, 2004, 5, 505-512.	1.4	11
195	CD21S antigen expression in tumour cells of diffuse large B-cell lymphomas is an independent prognostic factor indicating better overall survival. British Journal of Haematology, 2004, 125, 180-186.	2.5	13
196	Fluorescent In Situ Hybridization Analysis of Philadelphia Chromosome-Negative Chronic Myeloid Leukemia with the bcr/abl Fusion Gene. International Journal of Hematology, 2004, 80, 155-158.	1.6	7
197	Activities of granulocyte-macrophage colony-stimulating factor and interleukin-3 on monocytes. American Journal of Hematology, 2004, 75, 179-189.	4.1	25
198	Case of chronic-phase chronic myelogenous leukemia with an abdominal hematopoietic tumor of leukemic clone origin. American Journal of Hematology, 2004, 77, 167-170.	4.1	15

#	Article	IF	Citations
199	mRNA expression of leukemiaâ€associated antigens in patients with acute myeloid leukemia for the development of specific immunotherapies. International Journal of Cancer, 2004, 108, 704-711.	5.1	118
200	Quantization and similarity measure selection for discrimination of lymphoma subtypes under k-nearest neighbor classification. , 2004, 5328, 6.		3
201	Reprogramming of human postmitotic neutrophils into macrophages by growth factors. Blood, 2004, 103, 2973-2980.	1.4	50
202	Increased Membrane Proteinase 3 Expression on Neutrophils in Patients with Infectious Disease.. Blood, 2004, 104, 3806-3806.	1.4	0
203	Importance of CD4+ Helper T-cells in Antitumor Immunity. International Journal of Hematology, 2003, 77, 435-438.	1.6	43
204	Pharmacologic platelet anesthesia by glycoprotein IIb/IIIa complex antagonist and argatroban during in vitro extracorporeal circulation. Journal of Thoracic and Cardiovascular Surgery, 2003, 126, 428-435.	0.8	13
205	High plasma fibrinogen level is associated with poor clinical outcome in DIC patients. American Journal of Hematology, 2003, 72, 1-7.	4.1	75
206	Comparison of diagnostic criteria for disseminated intravascular coagulation (DIC): diagnostic criteria of the International Society of Thrombosis and Hemostasis (ISTH) and of the Japanese Ministry of Health and Welfare for overt DIC. American Journal of Hematology, 2003, 74, 17-22.	4.1	166
207	Increased Soluble Fibrin in Plasma of Patients with Disseminated Intravascular Coagulation. Clinical and Applied Thrombosis/Hemostasis, 2003, 9, 233-240.	1.7	31
208	The Blood Group P1 Synthase Gene Is Identical to the Gb3/CD77 Synthase Gene. Journal of Biological Chemistry, 2003, 278, 44429-44438.	3.4	60
209	CD4+ CD25+ T cells responding to serologically defined autoantigens suppress antitumor immune responses. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 10902-10906.	7.1	152
210	Good or Poor Responses of Hemostatic Molecular Markers in Patients with Hematopoietic Disorders After Treatment of Disseminated Intravascular Coagulation. Clinical and Applied Thrombosis/Hemostasis, 2003, 9, 71-77.	1.7	8
211	Elimination of CD4+ T cells may overcome suppression of anti-HER2 immune responses in tumor-bearing hosts. International Journal of Oncology, 2003, 22, 1135.	3.3	0
212	Relationship between Development of Nephrotoxicity and Blood Concentration of Cyclosporine A in Bone-Marrow Transplanted Recipients Who Received the Continuous Intravenous Infusion. Biological and Pharmaceutical Bulletin, 2003, 26, 1115-1119.	1.4	16
213	Measurement of tissue factor messenger RNA levels in leukocytes from patients in hypercoagulable state caused by several underlying diseases. Thrombosis and Haemostasis, 2003, 89, 660-665.	3.4	22
214	Microarray reveals differences in both tumors and vascular specific gene expression in de novo CD5+ and CD5- diffuse large B-cell lymphomas. Cancer Research, 2003, 63, 60-6.	0.9	46
215	Rapid lethality of hosts by interleukin-12 following H-2 compatible allogeneic bone marrow transplantation: Reminiscence of gut-associated acute graft-versus-host reaction. International Journal of Oncology, 2002, 21, 795.	3.3	0
216	Hemostatic Abnormalities Following Bone Marrow Transplantation. Clinical and Applied Thrombosis/Hemostasis, 2002, 8, 125-132.	1.7	9

#	Article	IF	Citations
217	Presentation of a major histocompatibility complex class 1â€“binding peptide by monocyte-derived dendritic cells incorporating hydrophobized polysaccharideâ€“truncated HER2 protein complex: implications for a polyvalent immuno-cell therapy. Blood, 2002, 99, 3717-3724.	1.4	112
218	De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients. Blood, 2002, 99, 815-821.	1.4	273
219	Adult acute myeloid leukemia cells do not express nonfunctional Ikaros isoforms. Blood, 2002, 100, 3436-3436.	1.4	3
220	Plasma Levels of Heparin Cofactor II (HCII) and Thrombin-HCII Complex in Patients with Disseminated Intravascular Coagulation. Clinical and Applied Thrombosis/Hemostasis, 2002, 8, 265-271.	1.7	9
221	Expression of tissue factor and vascular endothelial growth factor is associated with angiogenesis in colorectal cancer. American Journal of Hematology, 2002, 69, 247-254.	4.1	178
222	Two Independent Clones in Myelodysplastic Syndrome Following Treatment of Acute Myeloid Leukemia. International Journal of Hematology, 2002, 75, 182-186.	1.6	9
223	The Soluble Notch Ligand, Jagged-1, Inhibits Proliferation of CD34+ Macrophage Progenitors. International Journal of Hematology, 2002, 75, 269-276.	1.6	40
224	A Case of Acute Myeloid Leukemia with t(7;11)(p15;p15) Mimicking Myeloid Crisis of Chronic Myelogenous Leukemia. International Journal of Hematology, 2002, 76, 80-83.	1.6	5
225	Effect of direct infusion of antifungal agent on invasive pulmonary aspergillosis in a patient with acute leukemia. Journal of Infection and Chemotherapy, 2002, 8, 106-108.	1.7	3
226	Predicting response to plasma exchange in patients with thrombotic thrombocytopenic purpura with measurement of vWFâ€cleaving proteaseâ€ƒactivity. Transfusion, 2002, 42, 572-580.	1.6	121
227	HER2 peptide-specific CD8+ T cells are proportionally detectable long after multiple DNA vaccinations. Gene Therapy, 2002, 9, 879-888.	4.5	24
228	Regression of primary lymphoma of the ampulla of Vater after eradication of Helicobacter pylori. Gastrointestinal Endoscopy, 2001, 54, 92-96.	1.0	24
229	Inhibition by combined therapy with ticlopidine and aspirin of enhanced platelet aggregation during physical exercise in patients with coronary artery disease. American Heart Journal, 2001, 142, 5A-12A.	2.7	17
230	Activity and Antigen Levels of Thrombin-Activatable Fibrinolysis Inhibitor in Plasma of Patients With Disseminated Intravascular Coagulation. Thrombosis Research, 2001, 104, 1-6.	1.7	88
231	Comparison of the Responses of Global Tests of Coagulation with Molecular Markers of Neutrophil, Endothelial, and Hemostatic System Perturbation in the Baboon Model of E. coli Sepsis. Thrombosis and Haemostasis, 2001, 86, 1489-1494.	3.4	24
232	Endosonographic Images of Low-grade Lymphoma of Mucosa-associated Lymphoid Tissue After Radiotherapy. Journal of Clinical Gastroenterology, 2001, 33, 237-240.	2.2	7
233	Protein kinase Câ€“catalyzed phosphorylation of an inhibitory phosphoprotein of myosin phosphatase is involved in human platelet secretion. Blood, 2001, 97, 3798-3805.	1.4	57
234	Analysis of Clonal Relationship Using Single-Cell Polymerase Chain Reaction in a Patient with Concomitant Mantle Cell Lymphoma and Multiple Myeloma. International Journal of Hematology, 2001, 73, 383-385.	1.6	10

#	Article	IF	Citations
235	Efficient ex vivo generation of dendritic cells from CD14+ blood monocytes in the presence of human serum albumin for use in clinical vaccine trials. British Journal of Haematology, 2001, 114, 681-689.	2.5	22
236	Additional t(11;17)(q23;q21) in a patient with Philadelphia-positive mixed lineage antigen-expressing leukemia. Cancer Genetics and Cytogenetics, 2001, 126, 8-12.	1.0	19
237	Successful treatment with lowâ€dose splenic irradiation for massive splenomegaly in an elderly patient with hairyâ€cell leukemia. European Journal of Haematology, 2001, 67, 255-257.	2.2	11
238	Role of SEREX-defined immunogenic wild-type cellular molecules in the development of tumor-specific immunity. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 14571-14576.	7.1	61
239	Increased Plasma Thrombomodulin as a Vascular Endothelial Cell Marker in Patients With Thrombotic Thrombocytopenic Purpura and Hemolytic Uremic Syndrome. Clinical and Applied Thrombosis/Hemostasis, 2001, 7, 5-9.	1.7	26
240	Plasma Levels of Total Plasminogen Activator Inhibitor-I (PAI-I) and tPA/PAI-1 Complex in Patients With Disseminated Intravascular Coagulation and Thrombotic Thrombocytopenic Purpura. Clinical and Applied Thrombosis/Hemostasis, 2001, 7, 229-233.	1.7	37
241	HTLV-1 unrelated adult T-cell leukemia/lymphoma with unique phenotype and karyotype. , 2000, 64, 64-66.		3
242	Decreased tissue factor and tissue-plasminogen activator antigen in relapsed acute promyelocytic leukemia. American Journal of Hematology, 2000, 64, 145-150.	4.1	15
243	Plasma levels of activated protein C-protein C inhibitor complex in patients with hypercoagulable states. American Journal of Hematology, 2000, 65, 35-40.	4.1	28
244	Increased plasma levels of tissue factor pathway inhibitor-activated factor X complex in patients with disseminated intravascular coagulation. American Journal of Hematology, 2000, 65, 210-214.	4.1	8
245	A HER2/NEU-derived peptide, a Kd-restricted murine tumor rejection antigen, induces HER2-specific HLA-A2402-restricted CD8+ cytotoxic T lymphocytes. International Journal of Cancer, 2000, 87, 553-558.	5.1	36
246	A novel human HER2-derived peptide homologous to the mouse Kd-restricted tumor rejection antigen can induce HLA-A24-restricted cytotoxic T lymphocytes in ovarian cancer patients and healthy individuals. European Journal of Immunology, 2000, 30, 3338-3346.	2.9	46
247	Activity of interleukin 6 in the differentiation of monocytes to macrophages and dendritic cells. British Journal of Haematology, 2000, 109, 288-295.	2.5	83
248	BaxInduction Activates Apoptotic Cascade via Mitochondrial CytochromecRelease andBaxOverexpression Enhances Apoptosis Induced by Chemotherapeutic Agents in DLD-1 Colon Cancer Cells. Japanese Journal of Cancer Research, 2000, 91, 1264-1268.	1.7	43
249	Semiquantitative immunoblot analysis of nm23-H1 and -H2 isoforms in adenocarcinomas of the lung: Prognostic significance. Pathology International, 2000, 50, 200-205.	1.3	4
250	Acute promyelocytic leukemia with del(6)(p23). Leukemia Research, 2000, 24, 79-81.	0.8	8
251	Increased platelet aggregability in response to shear stress in acute myocardial infarction and its inhibition by combined therapy with aspirin and cilostazol after coronary intervention. American Journal of Cardiology, 2000, 85, 1054-1059.	1.6	43
252	Cyclin D1 expression is useful as a prognostic indicator for advanced esophageal carcinomas, but not for superficial tumors. Digestive Diseases and Sciences, 2000, 45, 864-869.	2.3	24

#	Article	IF	Citations
253	Development of a cancer vaccine: peptides, proteins, and DNA. Cancer Chemotherapy and Pharmacology, 2000, 46, S77-S82.	2.3	43
254	Successful treatment of lymphoid follicular proctitis with sulfasalazine suppositories. American Journal of Gastroenterology, 2000, 95, 2403-2404.	0.4	7
255	Changes of Hemostatic Molecular Markers After Gynecological Surgery. Clinical and Applied Thrombosis/Hemostasis, 2000, 6, 197-201.	1.7	6
256	State-of-the-Art Review : Elevated Tissue Factor Levels in Leukemic Cell Homogenate. Clinical and Applied Thrombosis/Hemostasis, 2000, 6, 14-17.	1.7	9
257	State-of-the-Art Review : Coagulation Tests and Anti-Phospholipid Antibodies in Patients Positive for Lupus Anticoagulant. Clinical and Applied Thrombosis/Hemostasis, 2000, 6, 144-150.	1.7	7
258	Eradication of Established Tumors by CD8+ T Cell Adoptive Immunotherapy. Immunity, 2000, 13, 265-276.	14.3	315
259	Hemostatic Abnormalities in Patients With Thrombotic Complications on Maintenance Hemodialysis. Clinical and Applied Thrombosis/Hemostasis, 2000, 6, 100-103.	1.7	19
260	Bcl-2 in Cell-Cycle Regulation of Hematopoietic Cells by Transforming Growth Factor-Î²1. Leukemia and Lymphoma, 2000, 39, 601-605.	1.3	6
261	Gastric mucosa-associated lymphoid tissue lymphoma with a focal high-grade component diagnosed by EUS and endoscopic mucosal resection for histologic evaluation. Gastrointestinal Endoscopy, 2000, 51, 752-755.	1.0	15
262	Diagnosis of Disseminated Intravascular Coagulation by Hemostatic Molecular Markers. Seminars in Thrombosis and Hemostasis, 2000, Volume 26, 017-022.	2.7	24
263	Increased Hemostatic Molecular Markers in Patients Undergoing Anticoagulant Therapy. Seminars in Thrombosis and Hemostasis, 2000, Volume 26, 113-118.	2.7	3
264	Successful treatment of lymphoid follicular proctitis with sulfasalazine suppositories. American Journal of Gastroenterology, 2000, 95, 2403-2404.	0.4	1
265	Expression of DCC Protein in Colorectal Tumors and Its Relationship to Tumor Progression and Metastasis. Oncology, 1999, 56, 134-141.	1.9	60
266	Agonist-Induced Regulation of Myosin Phosphatase Activity in Human Platelets Through Activation of Rho-Kinase. Blood, 1999, 93, 3408-3417.	1.4	94
267	State-of-the-Art Review : Outcome of Thrombotic Thrombocytopenic Purpura and Hemolytic Uremic Syndrome in Japan. Clinical and Applied Thrombosis/Hemostasis, 1999, 5, 110-112.	1.7	7
268	Attenuation of Interleukin 2 Signal in the Spleen Cells of Complex Ganglioside-lacking Mice. Journal of Biological Chemistry, 1999, 274, 13744-13747.	3.4	46
269	Survival of human leukaemic B-cell precursors is supported by stromal cells and cytokines: association with the expression of bcl-2 protein. British Journal of Haematology, 1999, 105, 701-710.	2.5	62
270	Myeloid differentiation antigen and cytokine receptor expression on acute myelocytic leukaemia cells with t(16;21)(p11;q22): frequent expression of CD56 and interleukin-2 receptor Î± chain. British Journal of Haematology, 1999, 105, 711-719.	2.5	25

#	Article	IF	Citations
271	De novo CD5-positive diffuse large B-cell lymphoma: clinical characteristics and therapeutic outcome. British Journal of Haematology, 1999, 105, 1133-1139.	2.5	68
272	Possible involvement of bcl-2 in regulation of cell-cycle progression of haemopoietic cells by transforming growth factor-beta1. British Journal of Haematology, 1999, 105, 470-477.	2.5	22
273	Tumor-specific targeting of T helper type 1 (Th1) cells by anti-CD3 Ã— anti-c-ErbB-2 bispecific antibody. Cancer Immunology, Immunotherapy, 1999, 48, 456-462.	4.2	5
274	Plasma concentration of itraconazole and its antifungal prophylactic efficacy in patients with neutropenia after chemotherapy for acute leukemia. Journal of Infection and Chemotherapy, 1999, 5, 213-216.	1.7	15
275	Increased truncated form of plasma tissue factor pathway inhibitor levels in patients with disseminated intravascular coagulation. , 1999, 60, 94-98.		19
276	Hemostatic molecular markers before the onset of disseminated intravascular coagulation. American Journal of Hematology, 1999, 60, 273-278.	4.1	55
277	Plasma sFas and sFas ligand levels in patients with thrombotic thrombocytopenic purpura and in those with disseminated intravascular coagulation. , 1999, 61, 21-25.		16
278	Changes of plasma hemostatic markers during percutaneous transluminal coronary angioplasty in patients with chronic coronary artery disease. , 1999, 61, 238-242.		26
279	Overexpression of Bax gene sensitizes K562 erythroleukemia cells to apoptosis induced by selective chemotherapeutic agents. Oncogene, 1998, 16, 1587-1591.	5.9	69
280	Poor outcome in disseminated intravascular coagulation or thrombotic thrombocytopenic purpura patients with severe vascular endothelial cell injuries. , 1998, 58, 189-194.		58
281	Hemostatic Molecular Markers Before Onset of Disseminated Intravascular Coagulation in Leukemic Patients. Seminars in Thrombosis and Hemostasis, 1998, 24, 293-297.	2.7	31
282	Immunohistochemical and Semiquantitative Immunoblot Analyses of Nm23-H1 and H2 Isoforms in Normal Human Tissues.. Acta Histochemica Et Cytochemica, 1998, 31, 411-418.	1.6	4
283	De Novo CD5+ Diffuse Large B-Cell Lymphomas Express VH Genes With Somatic Mutation. Blood, 1998, 91, 1145-1151.	1.4	92
284	Tissue Factor Expression and Metastatic Potential of Colorectal Cancer. Thrombosis and Haemostasis, 1998, 80, 894-898.	3.4	112
285	Increased soluble fibrin monomer and soluble thrombomodulin levels in non-insulin-dependent diabetes mellitus. Blood Coagulation and Fibrinolysis, 1997, 8, 303-307.	1.0	12
286	Regulation of Myosin Phosphatase Through Phosphorylation of the Myosin-Binding Subunit in Platelet Activation. Blood, 1997, 90, 3936-3942.	1.4	57
287	Increased tissue factor pathway inhibitor in patients with acute myocardial infarction. American Journal of Hematology, 1997, 55, 183-187.	4.1	43
288	K-ras gene mutations in intrahepatic bile duct tumors of Syrian golden hamsters. , 1997, 66, 97-103.		9

#	Article	IF	Citations
289	Increased plasma-soluble fibrin monomer levels in patients with disseminated intravascular coagulation. , 1996, 51, 255-260.		68
290	Plasma tissue factor and tissue factor pathway inhibitor levels in patients with disseminated intravascular coagulation. , 1996, 52, 165-170.		29
291	High establishment efficiency of lymph node stromal cells which spontaneously produce multiple cytokines derived from adult T-cell leukemia/lymphoma patients. International Journal of Oncology, 1996, 9, 619-24.	3.3	1
292	Differential Association of Protein Ser/Thr Phosphatase Types 1 and 2A with the Cytoskeleton upon Platelet Activation. Thrombosis and Haemostasis, 1996, 76, 1053-1062.	3.4	25
293	LIPOPROTEIN(A) AND EFFECTIVE RENAL PLASMA FLOW RATE IN OLDER PATIENTS WITH ARTERIOSCLEROTIC DISEASES. Journal of the American Geriatrics Society, 1995, 43, 1067-1068.	2.6	1
294	Decreased protein C inhibitor after percutaneous transluminal coronary angioplasty in patients with acute myocardial infarction. American Journal of Hematology, 1995, 49, 1-5.	4.1	29
295	Expression of ?2,8-sialyltransferase (GD3 synthase) gene in human cancer cell lines: high level expression in melanomas and up-regulation in activated T lymphocytes. Glycoconjugate Journal, 1995, 12, 894-900.	2.7	61
296	Substrate Specificity of Î²1,4-N-Acetylgalactosaminyltransferase in Vitro and in cDNA-transfected Cells. Journal of Biological Chemistry, 1995, 270, 6149-6155.	3.4	54
297	T cell receptor-mediated stimulation of mouse thymocytes induces up-regulation of the GM2/GD2 synthase gene. FEBS Letters, 1995, 358, 79-83.	2.8	20
298	Up-regulation of protein serine/threonine phosphatase type 2C during 1Î±,25-dihydroxyvitamin D3-induced monocytic differentiation of leukemic HL-60 cells. FEBS Letters, 1995, 375, 299-303.	2.8	11
299	Outcome of Disseminated Intravascular Coagulation in Relation to the Score when Treatment was Begun. Thrombosis and Haemostasis, 1995, 74, 848-852.	3.4	138
300	Decreased Plasma Tissue Factor Pathway Inhibitor Levels in Patients with Thrombotic Thrombocytopenic Purpura. Thrombosis and Haemostasis, 1995, 73, 010-014.	3.4	39
301	Established IL-2-dependent double-negative (CD4-CD8-) TCRÎ±Î²/CD3+ATL cells: induction of CD4 expression. British Journal of Haematology, 1994, 88, 234-241.	2.5	31
302	Reduced expression ofnm23-H1, but not ofnm23-H2, is concordant with the frequency of lymph-node metastasis of human breast cancer. International Journal of Cancer, 1993, 55, 66-71.	5.1	132
303	Expression ofnm23-Hl andnm23-H2 Proteins in Prostate Carcinoma. Japanese Journal of Cancer Research, 1993, 84, 1050-1054.	1.7	61
304	Immunohistochemical Analysis of Expression of nm23-H1/Nucleoside Diphosphate Kinase in Human Thyroid Carcinomas: Lack of Correlation Between Its Expression and Lymph Node Metastasis. Thyroid, 1993, 3, 105-109.	4.5	25
305	Molecular cloning and functional expression of the second mousenm23/NDP kinase gene,nm23-M2. FEBS Letters, 1992, 309, 358-362.	2.8	64
306	Distinguishing Pancreatic Carcinoma From Other Periampullary Carcinomas by Analysis of Mutations in the Kirsten-ras Oncogene. Annals of Surgery, 1991, 214, 657-662.	4.2	93

#	Article	IF	Citations
307	IL-2-Dependent ATL cell lines with phenotypes differing from the original leukemia cells. Leukemia Research, 1991, 15, 619-625.	0.8	35
308	Frequent Glycine-to-Aspartic Acid Mutations at Codon 12 of c-Ki-rasGene in Human Pancreatic Cancer in Japanese. Japanese Journal of Cancer Research, 1990, 81, 135-140.	1.7	95
309	Adult T cell leukaemia cells are of CD4+CDw29+T cell origin and secrete a B cell differentiation factor. British Journal of Haematology, 1989, 72, 370-377.	2.5	24
310	Localization and subcellular distribution of cellular ras gene products in rat brain. Molecular Brain Research, 1989, 5, 31-44.	2.3	50
311	Activated t-lymphocytes with polyclonal gammopathy in patients with human t-lymphotropic virus type i?associated myelopathy. Annals of Neurology, 1988, 24, 280-282.	5.3	58
312	Expression ofc-myc Oncogens Product andras Family Oncogene Products in Various Human Malignant Lymphomas Defined by Immunohistochemical Techniques. Cancer, 1988, 62, 2085-2093.	4.1	30
313	Binding ofrasp21 to bands 4.2 and 6 of human erythrocyte membranes. FEBS Letters, 1988, 226, 291-296.	2.8	7
314	Cytogenetic characterization of a T-cell line, ATN-1, derived from adult T-cell leukemia cells. Cancer Genetics and Cytogenetics, 1988, 34, 77-88.	1.0	21
315	Serological and Biochemical Characterization of Surface Antigens Expressed on Human Myeloid Cells and Identification of Six Distinct Antigen Systems. Acta Haematologica, 1988, 79, 61-67.	1.4	0
316	Cell-mediated cytotoxicity for cultured autologous melanoma cells. International Journal of Cancer, 1979, 24, 34-44.	5.1	55
317	A new differentiation antigen defining a subpopulation of mouse T cells. Nature, 1976, 261, 137-139.	27.8	11
318	EXPERIMENTAL MODELS AND THE ROLE OF RNA IN IMMUNOTHERAPY OF LEUKEMIA. Annals of the New York Academy of Sciences, 1973, 207, 430-441.	3.8	5
319	IL-3 can not replace GM-CSF in inducing human monocytes to differentiate into Langerhans cells. International Journal of Oncology, 0, , .	3.3	3